PMID- 37533215
OWN - NLM
STAT- MEDLINE
DCOM- 20230928
LR  - 20231003
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 12
IP  - 17
DP  - 2023 Sep
TI  - Effects of intrapericardial administration after catheter drainage on malignant 
      pericardial effusion in non-small cell lung cancer: A real-world study.
PG  - 18211-18218
LID - 10.1002/cam4.6404 [doi]
AB  - BACKGROUND: Malignant pericardial effusion (MPE) is a serious complication of 
      cancer that can be potentially deadly. It usually occurs in advanced or terminal 
      stages of the disease, and as a result, patients with MPE often have a poor 
      prognosis. There is a limited amount of research available that directly compares 
      the effectiveness and safety of intrapericardial drug administration following 
      pericardial drainage versus catheter drainage alone in non-small cell lung cancer 
      (NSCLC) patients who have MPE. METHODS: We retrospectively included 86 patients 
      with NSCLC with MPE at Zhejiang Cancer Hospital. Survival and recurrence 
      estimates were determined with the Kaplan-Meier method. RESULTS: We divided the 
      86 patients with NSCLC into two groups: a pericardial drainage group (34 out of 
      86, 39.5%) and an intrapericardial administration group (52 out of 86, 60.5%). 
      The response rates were 70.6% and 76.9% (p = 0.510), respectively. The median OS 
      was 132.0 and 234.0 days (p = 0.579), respectively. The median time to recurrent 
      drainage was 43.0 and 104.0 days (p = 0.170), respectively. The incidence of 
      adverse events (AEs) was 44.1% and 61.5% (p = 0.113), respectively. The most 
      frequent AEs were pain (27.9%) and fever (24.4%). Additionally, two patients in 
      the intrapericardial administration group died of cardiac arrest. CONCLUSIONS: 
      Compared with catheter drainage alone, intrapericardial medication infusion 
      during catheter drainage did not have significantly different effects. AEs 
      require close monitoring and management.
CI  - (c) 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Wei, Jingwen
AU  - Wei J
AUID- ORCID: 0000-0002-5020-0217
AD  - Department of Clinical Trial, The Cancer Hospital of the University of Chinese 
      Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.
AD  - Postgraduate training base Alliance of Wenzhou Medical University (Zhejiang 
      Cancer Hospital), Hangzhou, China.
FAU - Shi, Zheng
AU  - Shi Z
AUID- ORCID: 0000-0001-8282-3913
AD  - Department of Clinical Trial, The Cancer Hospital of the University of Chinese 
      Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.
AD  - Postgraduate training base Alliance of Wenzhou Medical University (Zhejiang 
      Cancer Hospital), Hangzhou, China.
FAU - Song, Zhengbo
AU  - Song Z
AUID- ORCID: 0000-0002-2226-0570
AD  - Department of Clinical Trial, The Cancer Hospital of the University of Chinese 
      Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.
AD  - Postgraduate training base Alliance of Wenzhou Medical University (Zhejiang 
      Cancer Hospital), Hangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230802
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Non-Small-Cell Lung/complications/drug therapy
MH  - *Pericardial Effusion/etiology
MH  - *Antineoplastic Agents/therapeutic use
MH  - *Lung Neoplasms/drug therapy
MH  - Retrospective Studies
MH  - *Cardiac Tamponade/complications/drug therapy
MH  - *Pleural Neoplasms/drug therapy
MH  - Catheters/adverse effects
MH  - Drainage/adverse effects
PMC - PMC10523995
OTO - NOTNLM
OT  - catheter drainage
OT  - intrapericardial administration
OT  - malignant pericardial effusion
OT  - non-small cell lung cancer
COIS- The authors have no relevant financial or non-financial interests to disclose.
EDAT- 2023/08/03 06:42
MHDA- 2023/09/28 06:42
PMCR- 2023/08/02
CRDT- 2023/08/03 01:03
PHST- 2023/07/05 00:00 [revised]
PHST- 2023/04/11 00:00 [received]
PHST- 2023/07/23 00:00 [accepted]
PHST- 2023/09/28 06:42 [medline]
PHST- 2023/08/03 06:42 [pubmed]
PHST- 2023/08/03 01:03 [entrez]
PHST- 2023/08/02 00:00 [pmc-release]
AID - CAM46404 [pii]
AID - 10.1002/cam4.6404 [doi]
PST - ppublish
SO  - Cancer Med. 2023 Sep;12(17):18211-18218. doi: 10.1002/cam4.6404. Epub 2023 Aug 2.